Business Development & Strategic Collaborations Director

NanoString Technologies
Job Location
530 Fairview Ave N,
Seattle, WA 98109
Competetive pay and benefits, Relocation assistance

Stock options, ESPP, PTO, Matching 401K, the Seattle experience, health, dental, vision, wellness reimbursement, and more...

Job Description

Position Summary:

Under the leadership of the Senior VP of Corporate and Business Development and as a key member of the Corporate and Business Development team, your primary responsibilities will be to:

1) Working with members of the cross-functional team, develop the strategic plan to enter and expand new business opportunities within disease areas of interest (i.e. hematology and/or solid tumors),

2) Drive business development process with biopharmaceutical companies for companion diagnostic and R&D collaborations, and related enabling collaborations and

3) Oversee and manage key strategic collaborations. This role will include all aspects of developing the strategy, and prospecting, evaluating, conducting diligence, transacting and implementing business and collaboration opportunities for NanoString.

You will work closely with cross functional partners and the executive management team to advance initiatives to support the corporate vision and goals.


  • In conjunction with team, develop the strategic plan to enter and expand new business opportunities within disease area franchises (i.e. hematology and/or solid tumors).
  • Be disease area knowledge owner by understanding the disease biology, influential KOLs, treatment paradigm, new and emerging diagnostics and new and emerging therapeutics.
  • Identify, develop and nurture scientific and business relationships within academia, biopharmaceutical companies and other stakeholders.
  • In conjunction with evaluation team, prioritize and license best-in-class content as basis for new diagnostic assays within the disease area franchise(s).
  • Enter value-creating companion diagnostic and R&D collaborations with premiere biopharmaceutical companies by applying best-practices across the business development process including:
  • Discover and prioritize potential collaboration opportunities with biopharmaceutical companies by actively prospecting, collaborating with cross-functional partners and leveraging your network.
  • Oversee and conduct robust analysis and due diligence to uncover and advance the highest potential opportunities.
  • Construct innovative, value-creating “win-win” deals to meet strategic and financial goals, and effectively negotiate successful outcomes.
  • Develop and champion the business case and strategic rationale with the Executive Management team and Board of Directors.
  • Take a leadership role in driving near-term implementation of the disease area strategy and strategic collaboration(s) and ultimately transition to the commercial team including:
  • Lead early strategic, relationship management and operational activities in conjunction with cross functional partners.
  • Gain alignment within all internal stakeholders as project advances to ensure proper integration into company systems.
  • Partner with commercial team to assure a smooth transfer of project
  • Be a proactive and inspirational advocate for NanoString. Develop compelling presentations to effectively open doors and energize potential partners.
  • Core contributor to Corporate & Business Development team to ensure individual and departmental goals are achieved by providing leadership, team support and driving other key initiatives.




Minimum B.S. degree in molecular biology, biochemistry, pharmacology or equivalent; higher level degree: MBA, PhD strongly preferred.

  • Track record of driving from inception to execution including valuation, diligence, deal engineering and leading negotiations with particular emphasis with pursuing and closing “sell side” value-creating deals with biopharmaceutical companies.
  • Strong scientific and technical acumen in oncology (including solid tumors, hematological and/or immune-oncology), personalized medicine and/or molecular diagnostics.
  • Robust understanding of the full drug development process, lifecycle management and commercialization of therapeutics.
  • Extensive experience in a diagnostic, biotech or pharmaceutical company.
  • A strategic thinker with outstanding business instincts who can help chart the course and translate into actionable, value-creating results for the company.
  • Solid network and reputation in the biopharmaceutical and diagnostic arenas.
  • Excellent analytical and organizational skills with the ability to make sound business judgments.
  • An ability to embrace teamwork and collaboration
  • Ability and willingness to travel.
  • Energetic, resourceful self-starter with high integrity, strong executive presence and the ability to work effectively in a dynamic, entrepreneurial environment.

Nanostring provides a competitive compensation and benefits package that includes bonus, stock options, Employee Stock Purchase Plan and 401(k) match. Nanostring is an equal opportunity employer.

About Our Organization

NanoString Technologies (NASDAQ:“NSTG”) provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 450 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity, reproducibility and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic kit to be marketed through the company's diagnostics business. Leveraging the company’s innovative platform and proven development, regulatory and commercial expertise , NanoString has established a companion diagnostics capability to enable biopharmaceuticals partners to translate biomarker discoveries into clinically-relevant diagnostics, helping to bring the right therapy to the right patient at the right time.

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.